Business
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML
85% remission rate observed in evaluable frontline AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed among evaluable patients; safety profile remains ...
About this update from Aptevo Therapeutics Inc.
[{"type":"text","content":"85% remission rate observed in evaluable frontline AML patients","length":63,"tagName":"p"},{"type":"text","content":"Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient","length":98,"tagName":"p"},{"type":"text","content":"No dose-limiting toxicities observed among evaluable patients; safety profile remains strong","length":92,"tagName":"p"},{"type":"text","content":"Evidence mounts for mipletamig as a potentially transformational addition to standard of care in frontline AML as targeted CD123 x CD3 approach showing power and precision, limited added toxicity","length":195,"tagName":"p"},{"type":"text","content":"Mipletamig Trial Momentum Builds as Cohort 3 Nears Full Enrollment at highest dose level evaluated to date in combination therapy","length":129,"tagName":"p"},{"type":"text","content":"SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced new clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig, its first-in-class CD123 x CD3 bispecific antibody, in combination with standard-of-care venetoclax and azacitidine (ven/aza) for newly diagnosed patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy.","length":604,"tagName":"p"},{"type":"text","content":"Across two trials, the mipletamig triplet therapy delivered remissions in 85% of evaluable frontline AML patients-which significantly exceeds results from competitor studies, including those achieved in the Viale A trial that evaluatedvenetoclax and azacitidine (ven/aza) as doublet therapy. These updated results from the RAINIER dose expansion trial continue to demonstrate a compelling efficacy advantage alongside a strong safety profile. No cytokine release syndrome (CRS) was observed in either cohorts 1 or 2. Cohort 3 Nears Full Enrollment at highest dose level evaluated to date in combination therapy.","length":611,"tagName":"p"},{"type":"text","content":""These results deepen our conviction in mipletamig's ability to elevate treatment outcomes for frontline AML patients who are not candidates for intensive chemotherapy," said ...